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Abstract. Background: The aim of the study was to evaluate
the response to and toxicity of pre-operative radiochemotherapy
containing raltitrexed (Tomudex) for resectable rectal
adenocarcinoma. Patients and Methods: From November
2000 to June 2002, 18 consecutive patients staged T3 N0/N+
were treated with pre-operative chemotherapy (3 mg/m2 of
raltitrexed on days 1, 19, 38) and concurrent radiotherapy
(RT) (50.4 Gy) in 6 weeks, followed by radical surgery within
8 weeks. Results: The treatment compliance was high. No
major acute toxicity was reported. Concerning late toxicity,
genitourinary adverse effects were prevalent. A complete
response was observed in one patient (6%), partial response in
eight (47%), stable disease in seven (41%) and progression in
one case. Three-year actuarial disease-free and overall survival
rates were 37% and 87.5%, respectively. Conclusion:
Raltitrexed did not increase the pathological response rate
compared with the rates obtained with use of preoperative RT
alone and reported in the literature. Acute morbidity was low
and acceptable, while late toxicity was considerable, prevalently
concerning sexual dysfunction and urinary complications. 
Rectal carcinoma is one of the most common cancers in the
United States and in Western Europe (1, 2). Local recurrence
after radical surgery is the major threat, occurring in 15% to
30% of patients and resulting in therapeutic failure and death
(3). Randomized trials have shown better results in terms of
local control and survival in patients treated with
postoperative radiochemotherapy when compared to surgery
alone. However, such an approach is correlated to significant
acute and chronic morbidity and may reduce the overall
compliance to treatment (4-7). In randomized studies of pre-
operative radiotherapy (RT) alone, promising results with
manageable toxicity were reported (8, 9). The addition of
chemotherapy in a neo-adjuvant setting should bring some
further advantages, based on the ability to act as an enhancer
of the RT response. Currently, new chemotherapeutic agents
are under investigation. In the present study, raltitrexed, a
quinazoline folate analog that acts as a specific thymidylate
synthase inhibitor and as a radiation sensitizer, was
administered for three cycles concomitantly with pre-
operative RT. This drug does not require the positioning of a
central catheter and has a long terminal half-life (260 hours)
(10). The aim of this phase II trial was to evaluate the toxicity
and response to treatment in patients with clinically
resectable locally-advanced rectal cancer.
Patients and Methods
Patients with resectable histologically-proven locally advanced
rectal adenocarcinoma were eligible for this study. The clinical
staging work-up consisted of computed tomography (CT) of
abdomen and pelvis, chest X-ray or CT, routine blood tests,
complete colonoscopy, endoscopic ultrasonography (EUS) and
rectal examination. Hematological, renal and liver toxicities were
graded by the National Cancer Institute Common Toxicity Criteria
(NCI-CTC) (11). Toxicity of the gastrointestinal tract,
genitourinary tract and skin were graded on the base of the
Radiation Therapy Oncology Group (RTOG) scale (12). Late
toxicity, registered 6 months after the completion of the neo-
adjuvant radiotherapy and on every follow-up visit, was evaluated
based on the Subjective Objective Management Analytic Late
Effect of Normal Tissue (SOMA/LENT) criteria (13). Tumor
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response was assessed according to the World Health Organization
(WHO) criteria (14). Down-staging was defined as any reduction
of stage between the clinical and pathological stage.
Pre-operative treatment protocol. Pre-operative radiotherapy was
delivered using a high-energy linear accelerator (15 MV). All patients
received 45 Gy in 25 fractions over 5 weeks to the whole pelvis
followed by a boost dose of 5.4 Gy in three fractions to the tumor mass
with a 2-3 cm margin, at 1.8 Gy per fraction (up to the total dose of
50.4 Gy). The whole pelvis was treated with four-field technique, while
the boost area was irradiated in the majority of patients with posterior-
anterior and two lateral fields (three-field technique). Customized
blocking, an immobilization system and hypogastric compressor were
used in all cases. Concurrent chemotherapy using raltitrexed at 3
mg/m2 was administered as a short i.v. infusion for about 15 min on
days 1, 19 and 38 (3 cycles). Six weeks after the end of RT, clinical and
radiological assessments (chest X-ray/CT, abdomen and pelvis CT and
EUS) were performed. Surgical resection was undertaken within 8
weeks from completion of the pre-operative RT to allow patient
recovery and maximum tumor shrinkage. 
Statistical analysis. This phase II trial was planned as two-stage trial
taking into account treatment response. The initial sample size
comprised 35 patients and an interim analysis was fixed for the first
18 cases. The aim was to achieve at least a 10% pathological
complete response rate. 
Disease-free and overall survival were calculated from the date
of surgery and assessed with the Kaplan-Meier methodology. The
response rate and toxicity were calculated as a simple ratio.
Results
From November 2000 to June 2002, 18 consecutive patients
entered the present clinical trial. The sociodemographic and
clinical patient characteristics are shown in Table I.
Treatment compliance. All but three out of the 18 patients
completed the planned three cycles of chemotherapy: one
patient refused the third cycle, two patients received only
two cycles due to transaminitis. The raltitrexed dose was
reduced by 25% in four patients and in one patient in the
second and third cycles, respectively. A 50% reduction was
made in one patient in the second and third cycles and in
one patient in the third cycle, due mainly to transaminitis.
None of the patients experienced grade 4 toxicity. There
was no delay of cycles. All patients received the prescribed
radiation dose and in four cases a short interruption of less
than a week was necessary. Post-operatively, all patients but
three (one refusal, one anasthomotic leakage, one complete
pathological response) received chemotherapy with adjuvant
intent of fluorouracil modulated by folinic acid. 
Surgery. After a median of 58 days from radiotherapy, 17
patients underwent surgery, while one patient refused.
Twelve patients underwent anterior resection of the
rectum (RAR) and the remaining five had abdomino-
perineal rectum resection (Miles’procedure). Distal and
radial margins were negative in all patients. In two cases,
one liver localization was detected intra-operatively and
was radically resected. Total mesorectal excision was
routinely performed. The median number of the examined
lymph nodes was eleven (range 3-23), while the number of
metastatic lymph nodes varied from zero to five (median
of 0.75). The median length of the surgery and of the
hospital stay was 215 min (range 95-360) and 13 days
(range 11-30), respectively. Out of the 17 operated
patients, six (35%) developed complications related to the
surgery but were treated conservatively: two anasthomotic
leakages, four wound infections managed with drainage
and antibiotics. No post-operative deaths occurred. 
Toxicity. Acute toxicity was monitored weekly during
treatment. There was no severe toxicity and no patient
required hospital admission because of acute reactions. The
incidence of acute and chronic toxicities is shown in Tables
II and III, respectively. 
Response evaluation. Upon pathological examination, one
patient (6%) showed a complete pathological response
(ypT0). A partial pathological response was achieved in eight
patients (47%) (two ypT1 and six ypT2). Seven additional
patients (41%) had stable disease. One patient (6%)
developed disease progression (ypT4). Overall, tumor down-
staging occurred in 53% of the patients (9/17). With regard to
lymph node down-staging, out of the seven patients with
ultrasound-staged nodal positive disease, three had no
pathological evidence of nodal involvement after
radiochemotherapy.
Local control and survival. The median follow-up was 37
months (range 28-49). Overall, twelve (71%) out of the 17
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Table I. Patient characteristics.
Characteristic No. of patients 














patients who completed the whole treatment were alive and
disease-free at last contact. Five patients developed
recurrent disease (in one case pelvic lymph nodes and in
four distant failure) and one of them died due to lung
metastasis. For all patients, the actuarial disease-free
survival rate at 3.4 years from surgery was 37% (95% CI,
0.09-1.0), while the actuarial overall survival rate was 87.5%
(95% CI, 0.673-1.0) (Figure 1).
Discussion
For rectal cancer, the primary end-points of
chemoradiotherapy are local control and survival (15-17).
Taking into account the quality of life of the patients, down-
staging, tumor resectability and sphincter preservation are
not less important objectives. The rationale of pre-operative
chemoradiotherapy is based on the assumption that it
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Table II. Acute toxicity.
Acute toxicity G1/G2 G3 G4
(n=18) n (%) n (%) n (%)
Transaminitis 8 (44%) 6 (33%) -
Leukopenia 2 (11%) 1 (5.5%) -
Anemia 3 (17%) - -
Asthenia 2 (11%) - -
Increased creatinine  level 1 (5.5%) - -
Diarrhea 9 (50%) 1 (5.5%) -
Tenesmus 7 (39%) - -
Rectal mucosal loss 1 (5.5%) - -
Abdominal pain 3 (17%) - -
Nausea/vomiting 2 (11%) - -
Dysuria 4 (22%) - -
Urinary frequency 3 (17%) - -
Urinary urgency 1 (5.5%) - -
Dermatitis 9 (50%) 3 (17%) -
Table III. Chronic toxicity.
Chronic toxicity G1/G2 G3 G4
(n=17) n (%) n (%) n (%)
Urinary frequency - 1 (6%) 2 (12%)
Urinary incontinence 1 (6%) - 2 (12%)
Decreased urinary stream 3 (18%) - -
Rectal mucosal loss* 1 (8%) 1 (8%) -
Stool frequency* 7 (58%) 1(8%) -
Sphincter control* 2 (17%) - -
Erectile dysfunction** 2 (17%) 1 (8%) 5 (42%)
Ejaculation dryness** - - 1 (8%)
Skin hypersensibility 3 (18%) - -
Perineal pain 2 (12%) 1 (6%) -
*Toxicity rate evaluated in patients who underwent anterior resection
of the rectum (12/17).
**Toxicity rate calculated in male patients (12/17).
Figure 1. Three-year actuarial disease-free survival (left) and  overall survival (right) among all patients.
should be as effective as in the post-operative setting but
less toxic (18, 19). For rectal cancer, the most common drug
used in combination with RT is fluorouracil, either in the
adjuvant or neo-adjuvant setting but, due to its short half-
life (8 min), a continuous infusion became necessary in
order to obtain response and to report good tolerance (20,
21). With the aim of reducing the disadvantages of the
venous central catheter, new chemotherapeutic agents, such
as capecitabine, oxaliplatin, tegafur and raltitrexed, are
currently under investigation (22-25). Previous phase I and
II trials supporting the use of raltitrexed not exceeding 
3 mg/m2 in association with RT have been conducted 
in several institutions with promising results in terms of
down-staging and toxicity (26-28). 
In our phase II trial, only one complete pathological
response, corresponding to 6%, was observed. This
compares unfavorably with the published rates in
chemoradiotherapy series that range from 10 to 35% (29-
31). Globally, tumor down-staging was observed in nine out
of 17 evaluable patients, corresponding to 53%. This value
is low compared to the other series (32). Moreover, the
incidence of partial response is very similar to the stable
disease rate (47% vs. 41%). Overall compliance to the
combined treatment was high. Fifteen out of 18 patients
completed the planned chemotherapy: the major dose-
limiting toxicity was benign transaminitis. The radiotherapy
compliance was very high; all 18 patients completed the
entire treatment without significant interruptions. Acute
toxicity can be considered acceptable: less than 20% of
patients developed grade 3 skin toxicity due to irradiation
of the perineal plane and the incidence of the grade 3
gastrointestinal toxicity was about 5%.
As far as late toxicity is concerned, the incidence of grade
3 toxicity was limited, while grade 4 toxicity was significantly
high, especially for the genitourinary tract and sexual
function. Such high rates are impressive and can have both
surgery- and radiochemotherapy-related etiology. Most
patients suffered from urinary dysfunctions, but only males
complained about sexual problems (five patients had grade
4 impotence). The data on the long-term morbidity show
that short-course pre-operative radiotherapy has an adverse
effect on sexual activity and function for both male and
female patients (33, 34). The median duration of the surgery
(215 min) was not influenced by the neo-adjuvant
treatment, but the surgeons encountered more difficulties
in dissecting the mesorectum because of the initial fibrosis.
In our series, the post-operative complication rate
compared favorably with those observed in other
institutions. The clinical management was easy and did not
require prolonged hospitalization. There was no post-
operative mortality.
In conclusion, the feasibility and low acute toxicity of pre-
operative radiochemotherapy containing ratiltrexed were
indicated. However, the low response rate and relatively
high incidence of late toxicity call for new studies that focus
on the integration of novel agents expressing radio-
sensitizing or anti-angiogenic properties with altered
fractionation and/or dose-escalation radiotherapy schedules. 
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